• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

白癜风患者的全因死亡率和死因特异性死亡率:韩国一项全国范围内基于人群的研究。

All-Cause and Cause-Specific Mortality among Patients with Vitiligo: A Nationwide Population-Based Study in Korea.

机构信息

Department of Dermatology, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.

Department of Dermatology, College of Medicine, Yonsei University, Wonju, Korea.

出版信息

J Invest Dermatol. 2024 Jan;144(1):125-132.e3. doi: 10.1016/j.jid.2023.07.007. Epub 2023 Jul 29.

DOI:10.1016/j.jid.2023.07.007
PMID:37517513
Abstract

Vitiligo is a common autoimmune skin disorder; however, there is limited information about risks of mortality among patients with vitiligo. Therefore, we aimed to investigate the mortality in patients with vitiligo. A population-based cohort study was conducted using the data linkage of the National Health Insurance Service database and the National Death Registry. Patients with incident vitiligo were matched with sociodemographic factors-matched controls without vitiligo in a 1:5 ratio. All-cause and cause-specific mortalities were compared between patients with vitiligo and controls. In total, 107,424 patients with incident vitiligo and 537,120 matched controls were included. The mortality rates were 34.8 and 45.3 per 10,000 person-years in patients and controls, respectively. Patients with vitiligo showed a significantly lower risk of mortality (adjusted hazard ratio = 0.75, 95% confidence interval = 0.72-0.78). The cause-specific mortality from infectious diseases, oncologic diseases, hematologic diseases, endocrine diseases, neurologic diseases, cardiovascular diseases, respiratory diseases, and renal/urogenital disease was significantly lower in patients with vitiligo. Patients with vitiligo were associated with a lower risk of mortality, suggesting that vitiligo-associated autoimmunity might contribute to reduced morbidity and mortality.

摘要

白癜风是一种常见的自身免疫性皮肤疾病;然而,关于白癜风患者的死亡率风险信息有限。因此,我们旨在研究白癜风患者的死亡率。本研究采用国家健康保险服务数据库和国家死亡登记处的数据链接,进行了一项基于人群的队列研究。按照社会人口因素,将新诊断的白癜风患者与无白癜风的对照组以 1:5 的比例进行匹配。比较了白癜风患者和对照组的全因死亡率和死因特异性死亡率。共纳入了 107424 例新发白癜风患者和 537120 例匹配对照。患者和对照组的死亡率分别为每 10000 人年 34.8 和 45.3。白癜风患者的死亡率显著降低(调整后的危险比=0.75,95%置信区间=0.72-0.78)。与对照组相比,白癜风患者因传染病、肿瘤疾病、血液疾病、内分泌疾病、神经疾病、心血管疾病、呼吸系统疾病和肾脏/泌尿生殖系统疾病而导致的死因特异性死亡率显著降低。白癜风患者的死亡率较低,这表明白癜风相关的自身免疫可能有助于降低发病率和死亡率。

相似文献

1
All-Cause and Cause-Specific Mortality among Patients with Vitiligo: A Nationwide Population-Based Study in Korea.白癜风患者的全因死亡率和死因特异性死亡率:韩国一项全国范围内基于人群的研究。
J Invest Dermatol. 2024 Jan;144(1):125-132.e3. doi: 10.1016/j.jid.2023.07.007. Epub 2023 Jul 29.
2
All-Cause and Cause-Specific Mortality Risks among Patients with Hidradenitis Suppurativa: A Korean Nationwide Population-Based Cohort Study.化脓性汗腺炎患者的全因和病因特异性死亡率:一项韩国全国基于人群的队列研究。
J Invest Dermatol. 2023 Jun;143(6):944-953.e8. doi: 10.1016/j.jid.2022.11.019. Epub 2022 Dec 22.
3
The incidence and survival of melanoma and nonmelanoma skin cancer in patients with vitiligo: a nationwide population-based matched cohort study in Korea.白癜风患者中黑色素瘤和非黑色素瘤皮肤癌的发病率及生存率:韩国一项基于全国人群的配对队列研究
Br J Dermatol. 2020 Apr;182(4):907-915. doi: 10.1111/bjd.18247. Epub 2019 Sep 18.
4
Markedly Reduced Risk of Internal Malignancies in Patients With Vitiligo: A Nationwide Population-Based Cohort Study.白癜风患者发生内部恶性肿瘤的风险显著降低:一项全国范围内基于人群的队列研究。
J Clin Oncol. 2019 Apr 10;37(11):903-911. doi: 10.1200/JCO.18.01223. Epub 2019 Feb 20.
5
Pregnancy outcomes in patients with vitiligo: A nationwide population-based cohort study from Korea.韩国一项全国性基于人群的队列研究:白癜风患者的妊娠结局。
J Am Acad Dermatol. 2018 Nov;79(5):836-842. doi: 10.1016/j.jaad.2018.02.036. Epub 2018 Mar 1.
6
Association of All-Cause and Cause-Specific Mortality Risks With Pyoderma Gangrenosum.坏疽性脓皮病与全因和病因特异性死亡率风险的关联。
JAMA Dermatol. 2023 Feb 1;159(2):151-159. doi: 10.1001/jamadermatol.2022.5437.
7
Mortality and morbidity in patients with osteogenesis imperfecta in Denmark.丹麦成骨不全患者的死亡率和发病率。
Dan Med J. 2018 Apr;65(4).
8
Vitiligo and overt thyroid diseases: A nationwide population-based study in Korea.白癜风与显性甲状腺疾病:韩国全国范围内基于人群的研究。
J Am Acad Dermatol. 2017 May;76(5):871-878. doi: 10.1016/j.jaad.2016.12.034. Epub 2017 Feb 24.
9
Prevalence and incidence of vitiligo and associated comorbidities: a nationwide population-based study in Korea.白癜风及其相关合并症的患病率和发病率:韩国一项基于全国人口的研究
Clin Exp Dermatol. 2023 Apr 27;48(5):484-489. doi: 10.1093/ced/llad028.
10
Increased risk of psychiatric disorders in adult patients with vitiligo: A nationwide, population-based cohort study in Taiwan.台湾一项全国性基于人群的队列研究显示,白癜风成年患者患精神障碍的风险增加。
J Dermatol. 2020 May;47(5):470-475. doi: 10.1111/1346-8138.15290. Epub 2020 Mar 2.

引用本文的文献

1
Assessment of the Influence of UVR in Cutaneous Melanoma.紫外线辐射对皮肤黑色素瘤影响的评估
Photodermatol Photoimmunol Photomed. 2025 May;41(3):e70024. doi: 10.1111/phpp.70024.
2
Cardiovascular risk in vitiligo: time for integration of clinical evaluation and echocardiography in management of patients?白癜风患者的心血管风险:是时候将临床评估和超声心动图纳入患者管理了吗?
Arch Dermatol Res. 2025 Feb 17;317(1):429. doi: 10.1007/s00403-025-03917-5.
3
Recent clinical and mechanistic insights into vitiligo offer new treatment options for cell-specific autoimmunity.
近期对白癜风的临床和机制研究为细胞特异性自身免疫提供了新的治疗选择。
J Clin Invest. 2025 Jan 16;135(2):e185785. doi: 10.1172/JCI185785.
4
Vitiligo is associated with lower body mass index: a retrospective case-control study.白癜风与较低的体重指数相关:一项回顾性病例对照研究。
Br J Dermatol. 2025 Mar 18;192(4):753-755. doi: 10.1093/bjd/ljae478.
5
Vitiligo is associated with an increased risk of cardiovascular diseases: a large-scale, propensity-matched, US-based retrospective study.白癜风与心血管疾病风险增加相关:一项基于美国的大规模、倾向匹配的回顾性研究。
EBioMedicine. 2024 Nov;109:105423. doi: 10.1016/j.ebiom.2024.105423. Epub 2024 Oct 25.